IO Biotech (IOBT) said Friday that an Independent Data Monitoring Committee has recommended the continuation of its late-stage trial of vaccine candidate IO102-IO103 in combination with Merck's (MRK) Keytruda as a first-line treatment for patients with unresectable or metastatic melanoma.
No new safety signals were observed at interim analysis, the clinical-stage biopharmaceutical company said. The primary endpoint of progression-free survival is projected to be reached in the first half of 2025.
Price: 1.4400, Change: -0.06, Percent Change: -4.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments